

The SARS-CoV-2 spike protein induces long-term transcriptional perturbations of mitochondrial metabolic genes, causes cardiac fibrosis, and reduces myocardial contractile in obese mice



Xiaoling Cao^{1,7}, Vi Nguyen^{1,7}, Joseph Tsai², Chao Gao¹, Yan Tian^{1,3}, Yuping Zhang^{1,4}, Wayne Carver^{1,5}, Hippokratis Kiaris⁶, Taixing Cui^{1,5}, Wenbin Tan^{1,5,*}

ABSTRACT

Background: As the pandemic evolves, post-acute sequelae of CoV-2 (PASC) including cardiovascular manifestations have emerged as a new health threat. This study aims to study whether the Spike protein plus obesity can exacerbate PASC-related cardiomyopathy.

Methods: A Spike protein-pseudotyped (Spp) virus with the proper surface tropism of SARS-CoV-2 was developed for viral entry assay *in vitro* and administration into high fat diet (HFD)-fed mice. The systemic viral loads and cardiac transcriptomes were analyzed at 2 and 24 h, 3, 6, and 24 weeks post introducing (wpi) Spp using RNA-seq or real time RT-PCR. Echocardiography was used to monitor cardiac functions.

Results: Low-density lipoprotein cholesterol enhanced viral uptake in endothelial cells, macrophages, and cardiomyocyte-like H9C2 cells. Selective cardiac and adipose viral depositions were observed in HFD mice but not in normal-chow-fed mice. The cardiac transcriptional signatures in HFD mice at 3, 6, and 24 wpi showed systemic suppression of mitochondria respiratory chain genes including ATP synthases and nicotinamide adenine dinucleotide:ubiquinone oxidoreductase gene members, upregulation of stress pathway-related crucial factors such as nuclear factor-erythroid 2-related factor 1 and signal transducer and activator of transcription 5A, and increases in expression of glucose metabolism-associated genes. As compared with the age-matched HFD control mice, cardiac ejection fraction and fractional shortening were significantly decreased, while left ventricular end-systolic diameter and volume were significantly elevated, and cardiac fibrosis was increased in HFD mice at 24 wpi.

Conclusion: Our data demonstrated that the Spike protein could induce long-term transcriptional suppression of mitochondria metabolic genes and cause cardiac fibrosis and myocardial contractile impairment in obese mice, providing mechanistic insights to PASC-related cardiomyopathy.

© 2023 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Keywords COVID-19; Cardiomyopathy; Post-acute sequelae of CoV-2; Obesity; Mitochondria; Respiratory chain complex; ATP synthases; NDUF

1. INTRODUCTION

Coronavirus disease 19 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a positive-sense single-stranded RNA virus [1]. Viral entry is mediated through the binding of angiotensin converting enzyme 2 (ACE2) with the Spike protein [2]. In addition, neuropillin (NRP) 1 has been identified as an additional host factor for viral entry, which is thought to be ACE2-independent [3,4]. The Spike protein alone can induce multiple intracellular pathologies. It can increase levels of the hemeoxygenase-

1 in kidney cell lines [5], impair endothelial mitochondria functions through downregulation of ACE2 [6], result in natural killer cell-reduced degranulation in lung epithelial cells [7], and disrupt human cardiac pericytes function through CD147-receptor-mediated signaling [8]. We recently have found that the Spike protein impairs lipid metabolism and increases susceptibility to lipotoxicity [9].

Metabolic-associated preconditions such as diabetes mellitus (DM), cardiovascular disorders (CVD), hypertension, and obesity are risk factors for patients with COVID-19 to develop severe symptoms [10]. Our studies have shown decreased levels of total cholesterol (TC), low

¹Department of Cell Biology and Anatomy, School of Medicine, University of South Carolina, Columbia, SC, 29209, USA ²Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, UC San Diego School of Medicine, San Diego, CA, 92093, USA ³Department of Obstetrics and Gynecology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China ⁴Department of General Surgery, The 3rd Xiangya Hospital of Central South University, Changsha, Hunan, 410013, China ⁵Department of Biomedical Engineering, College of Engineering and Computing, University of South Carolina, Columbia, SC, 29208, USA ⁶Drug Discovery & Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, 29208, USA

⁷ Xiaoling Cao and Vi Nguyen contributed equally to this work.

*Corresponding author. Department of Cell Biology and Anatomy, School of Medicine, and Department of Biomedical Engineering, College of Engineering and Computing, University of South Carolina, Columbia, SC, 29209, USA. E-mail: wenbin.tan@uscmcd.edu (W. Tan).

Received April 7, 2023 • Revision received June 6, 2023 • Accepted June 16, 2023 • Available online 20 June 2023

<https://doi.org/10.1016/j.molmet.2023.101756>

Abbreviations:

ACE2	angiotensin converting enzyme 2
COVID-19	coronavirus disease 2019
CVD	cardiovascular disorders
EF	ejection fraction
FS	fractional shortening
HFD	high fat diet
LDL-c	low-density lipoprotein cholesterol
MRC	mitochondria respiratory chain
NCF	normal-chow-fed
NDUF	nicotinamide adenine dinucleotide:ubiquinone oxidoreductase family
NFE2L1	nuclear factor-erythroid 2-related factor 1
PASC	post-acute sequelae of CoV-2
SARS-CoV-2	severe acute respiratory syndrome coronavirus 2
Spp	spike protein-pseudotyped lentivirus
SRB1	scavenger receptor class B type 1
STAT5A	signal transducer and activator of transcription 5A
TMP	transcripts per million

density lipoprotein cholesterol (LDL-c) and high density lipoprotein cholesterol (HDL-c) in patients with COVID-19, which are associated with disease severity and mortality [11–14]. Mechanistically, lipids have been shown to be a critical contributor to transmission, replication, and transportation for coronaviruses. For example, lipid rafts have been reported to be necessary for SARS virus replication [15]. SARS-CoV-2 Spike protein confers a hydrophobic binding pocket of free fatty acid (FFA), linoleic acid (LA) and cholesterol [16,17]. The Spike protein alone can impair lipid metabolism in host cells [9]. These lines of evidence have demonstrated that lipids and obesity are important mechanistic factors for COVID-19 severity.

Incomplete recovery has been reported in many COVID-19 patients who have persistent symptoms months beyond the acute stage. The post-acute sequelae of CoV-2 (PASC) or long-COVID is defined as persistence of symptoms and/or long-term complications beyond 4 weeks of SARS-CoV-2 infection or onset of symptoms [18,19]. Symptoms of PASC have a diverse range with multiorgan involvement [18,19]. Particularly, CVD sequelae are among major manifestations of PASC which may include dyspnea, palpitation, chest pain, myocardial fibrosis, arrhythmias, and increased cardiometabolic demand [18,19]. In addition, COVID-19 survivors have an increased risk of incident CVD spanning multiple categories within one year [20]. Obesity is a major risk factor for PASC [21]. Particularly, microvascular injuries caused by SARS-CoV-2 infection are thought to be among the contributive factors to cardiac sequelae of PASC. However, the underlying mechanisms have not been determined.

2. METHODS

2.1. Materials

Human dermal microvascular endothelial cells (hDMVECs) and endothelial cell (EC) culture medium were purchased from ScienCell (San Diego, CA, USA). Phoenix cells and Dulbecco's Modified Eagle Medium (DMEM) were purchased from ATCC (Manassas, VA, USA). Lentiviral vector pLV-mCherry were obtained from Addgene (Watertown, MA, USA). Coding sequence of SARS-CoV-2 Spike gene (Wuhan variant, GenBank: QHU36824.1) and the expression vector were described previously [22]. LDL-c, HDL-c and lipoprotein depleted fetal bovine

serum (LD-FBS) were obtained from Kalen Biomedical, LLC (Germantown, MD, USA). Sulfo-NHS-LC-biotin and desalting spin column were obtained from ThermoFisher (Waltham, MA, USA). The sources of antibodies were listed in the [Supplementary Table 1](#). Primers were synthesized by IDT (Coralville, IA, USA) and listed in [Supplementary Table 2](#). The animal protocol was approved by the IACUC committee at the University of South Carolina, Columbia. C57BL/6J wild type and LDL receptor (LDLR) KO (B6.129S7-Ldlr^{tm1her/J}) mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). The generation of Spp virus was previously reported [22].

2.2. In vitro LDL-c and Spp lentivirus binding assay

Human LDL-c and HDL-c were biotinylated using Sulfo-NHS-LC-biotin and purified using a 10Kd-cut off desalting column (ThermoFisher, Waltham, MA, USA). The biotin-LDL-c (2 µg) or biotin-HDL-c (2 µg) was incubated with different quantities of Spp virus (1–32 million particles) for 1 h at room temperature in PBS. The biotin-LDL-c/lentivirus or biotin-HDL-c/lentivirus complex were pulled down and washed three times. The virus bound with biotin-LDL-c or HDL-c was quantified using real time RT-PCR to determine the copy of mCherry gene.

2.3. LDL-c-mediated Spp viral cell entry assay

C57BL/6J wild type and LDLR KO (B6.129S7-Ldlr^{tm1her/J}) mice were intraperitoneally injected by 3% brewer thioglycollate medium (Millipore-Sigma, St. Louis, MO, USA). Mouse peritoneal cavity elicited macrophages (MØ) were collected, isolated, and cultured in serum-free DMEM/F12 medium for overnight prior to Spp viral entry assay. Primary hDMVECs were cultured in EC medium with 5% FBS. Cardiomyocytes-like H9C2 cells (ATCC, Manassas, VA, USA) were cultured in DMEM (10% FBS) medium. Both hDMVECs and H9C2 cells are plated to 60% confluence and were incubated with 2% LD-FBS (cholesterol levels <0.8 µg/mL) in the medium for overnight prior to assays. Spp virus (4.8×10^7 particles) was incubated with human LDL-c (12.5 µg) for 1 h at room temperature. The Spp lentivirus alone or Spp/LDL-c mixture containing the same quantity of viral particles were added into cells and incubate through 30 min to 16 h. The cells were washed by PBS three time and RNAs were extracted using a Zymo RNA extraction kit (Zymo Research, Irvine, CA, USA). The uptake of Spp virus by cells was determined using a real time RT-PCR. Beta-actin was used as an internal amplification control for normalization. For inhibitory experiments, a scavenger receptor class B type 1 (SRB1) antagonist, block lipid transport-1 (BLT-1), was added into the cells to a final concentration of 10 µM for 2 h prior to addition of the Spp virus.

2.4. Viral administration in vivo

C57BL/6J wild type male mice (8 weeks old) from the same cohort were obtained from the Charles River Labs (Wilmington, MA, USA) and fed normal chows or high fat diet (HFD) (40% fat, TD.95217, Envigo, Indianapolis, IN, USA) for 5 months. C57BL/6J mice will typically gain 20–30% in body weight and develop a full manifested spectrum of obesity after 4–5 months of HFD feeding [23]. In order to achieve 80% power to detect a standardized effect size (means/standard deviation) of 0.80 at alpha = 0.05 level, 6 animals per group were randomly assigned for normal-chow-fed (NCF) mice using the simple randomization method. For HFD mouse groups, 10–12 animals per group were randomly assigned. About 1/3 of mice were unsuccessful to gain weights under HFD thus were removed from the study. We used male mice in this study since males are more susceptible to develop cardiomyopathy and post-viral cardiac inflammation than females and that testosterone drives the inflammatory response to increase heart

disease in males, which is a sex difference observed in COVID-19 [24–26]. The Spp virus (8×10^8 particles) was intravenously administered. The animals were continuously fed normal chows or HFD until the endpoints of the experiments. The animals were sacrificed at 2 or 24 h post-introducing (hpi) Spp, 3 or 4 days post introducing (dpi) Spp, 3, 6, or 24 weeks post introducing (wpi) Spp and perfused by 50 mL PBS per mouse. The tissues including lungs, heart, liver, kidney, aorta, adipose tissue, and spleen were collected. In general, one part of tissue was used for RNA extraction followed by a real time RT-PCR to determine the number of viral particles in each tissue. The other part was fixed, embedded, and used for histology and immunohistochemistry.

2.5. RNA-seq

The cardiac RNA-seq was carried out in the following groups of both normal chow and HFD fed mice: control (prior to viral administration), 24 hpi and 3 wpi. The total cardiac RNAs ($n = 3$ animals per group) were extracted using a Qiagen RNA isolation kit. The ribosomal RNAs were depleted using a Qiagen rRNA HMR kit. RNA-seq libraries were constructed using a Qiagen Standard RNA Library kit followed by the manufacture manual (Qiagen, Hilden, Germany). The insertion size of the library was determined using an Agilent 2100 Bioanalyzer system (Santa Clara, CA, USA). Library quantification was carried out using a NGS library quantification kit from Takara Bio (Kusatsu, Shiga, Japan). NGS was performed on a NovaSeq 6000 system (Illumina, San Diego, CA, USA) targeting for 25 - 50 M reads per library. The raw reads were aligned and mapped to mouse reference genome using STAR [27]. Validation and quantification of RNA transcripts were performed using FeatureCounts [28]. Biostatistical analysis for genes with differential expression (DE) among groups and data graphic generation were carried out using EdgeR in the Rstudio package (<https://www.rstudio.com/>). False discovery rate (FDR) < 0.05 was considered significant.

2.6. Echocardiography

The HFD mice at 24 wpi and age-matched HFD control mice (13 months old) were anesthetized and echocardiography was performed using the VisualSonics Vevo 2100 system (VisualSonics, Inc. Toronto, Canada) with a previously reported procedure [29].

2.7. Statistical analyses

All statistical analysis (except RNA-seq) were performed in Origin 2019 (Northampton, MA, USA). The student two sample *t* test was used for two groups comparisons test. The data was presented as “mean \pm s.d.” and $p < 0.05$ was considered as significant.

3. RESULTS

3.1. LDL-c binds to Spp and facilitates viral entry via SR-B1

In order to test whether Spike protein could be directly associated with lipoprotein cholesterols, we performed a binding assay between LDL-c or HDL-c and Spp virus. The Spp virus bound with biotin-LDL-c or biotin-HDL-c was quantified. Spp virus showed two times maximal binding affinity with LDL-c than HDL-c (Figure 1A). LDL-c showed ten times higher binding capacity with Spp than a regular VSV-G lentivirus (Figure 1A). HDL-c showed similar binding capacities with Spp to VSV-G lentivirus (Figure 1A), suggesting that HDL-c is non-selective to both types of surface glycoproteins on viruses.

The binding preference of Spp to LDL-c let us focus on the potential role of LDL-c in facilitation of Spp cell entry in cardiovascular system. The HDMVECs, mouse peritoneal cavity elicited M \emptyset , and cardiomyocyte-like H9C2 cells were used in this assay. The cellular

uptake of Spp virus was significantly increased in the presence of LDL-c in 0.5–2 h in HDMVECs, 2–6 h in M \emptyset , and 2 h in H9C2 cells as compared with Spp alone (Figure 1B–E, Supplementary Figure 1). A recent report has shown that SARS-2 can bind to HDL-c and enter into cells via SR-B1 [30]. We next investigated whether SR-B1 mediated LDL-c-enhanced Spp uptake in cells. We found that the SR-B1 inhibitor BLT-1 could significantly block the LDL-c-augmented Spp entry in HDMVEC, M \emptyset , and H9C2 (Figure 1B, C, and E). Interestingly, uptake of Spp in LDLR $^{-/-}$ M \emptyset showed a substantial increase in the presence of LDL-c, which could be fully blocked by BLT-1 (Figure 1D). In addition, an anti-LDLR antibody failed to block the LDL-c-augmented Spp entry in HDMVEC (data not shown). This data demonstrates that SR-B1, but not LDLR, accounts for LDL-c-enhanced Spp cellular uptake.

3.2. Selective cardiac viral accumulation in obese mice

The timeline of the animal study protocol was shown in Figure 2A. The serum levels of total cholesterol, LDL-c/VLDL-c, and HDL-c were significantly elevated in HFD mice as compared with the mice fed by NCF (Figure 2B). The protein levels of SR-B1 were significantly increased in heart, adipose tissue and kidney, but not in liver, lung and spleen, in HFD mice as compared with NCF mice (Figure 2C, Supplementary Figure 2). In our previous report, we have shown that Spp entered various tissues including adipose tissues, the heart, lungs, the liver, kidneys and the spleen in normal chow-fed mice with the highest level in the lungs at 2 hpi [22]. At 24 hpi, the Spp was effectively removed from these tissues except adipose tissues in which it was instead further increased (*, $p < 0.05$, Figure 2B). Intriguingly, the pattern of Spp viral trafficking was shifted in HFD-fed mice, which was characterized by a selective increase in the heart, kidney, aorta and adipose tissues at 2 hpi and remained accumulation in those tissues except kidney at 24 hpi (&, $p < 0.05$, Figure 2D). Since the Spp virus was replication incompetent, the viral particles were rapidly cleared in mice and undetectable 3–4 dpi in both NCF and HFD-fed mice using real time RT-PCR assay (data not shown), which could be equivalent to the viral-free stage in discharged COVID-19 patients. The timelines of 3 and 6 wpi could be used as animal models to mimic cardiac sequelae in PASC as we studied their cardiac transcripts below. At 2 and 24 hpi in HFD mice, the cellular locations of Spp virus could be detected in cardiac capillaries and big caliber vessels using co-immunostaining of anti-Spike S1 subunit and anti-CD31 antibodies (Figure 2E). A small number of scattered cardiac MRC1 $^{+}$ M \emptyset was observed to have an uptake of Spp virus (Figure 2E). Due to the sensitivity of immunoassay, we could hardly detect any cellular location of Spike protein in hearts in NCF mice at 2 and 24 hpi (data not shown), which was consistent with the presence of very low viral RNA levels in hearts in those animals (Figure 2D).

3.3. Acute cardiac transcriptional responses in obese mice post Spp administration

There were 30 DE genes (FDR<0.05) including 19 upregulated and 11 downregulated transcripts in the NCF mice after 24 hpi as compared with the NCF mice without viral administration (Supplementary Figures 3A and 4A, Supplementary Table 3). This result was consistent with our previous data showing that cardiac viral loads were almost eliminated in NCF mice post 24 hpi [22], which reasonably resulted in very mild transcriptome changes. After 24 hpi, there were total 434 DE genes (FDR<0.05) in the HFD mice as compared with the NCF mice (Supplementary Figures 3B and 4B, Supplementary Table 4). There were total 548 DE genes (FDR<0.05) in the HFD mice after 24 hpi as compared with the HFD control mice without viral administration




Figure 1: LDL-c augments Spp viral entry which can be blocked by a SR-B1 inhibitor BLT-1. (A) Spp virus shows a higher maximal binding affinity to LDL-c than HDL-c. The biotinylated LDL-c and HDL-c were incubated with various quantities of Spp virus ($n = 4$). The lipoprotein cholesterol bound virus was determined by mCherry RNA copies. (B–E) LDL-c significantly increases cellular uptake of Spp virus in HDMVEC ($n = 6–13$) (B), MØ ($n = 5$) (C), LDLR^{-/-} MØ ($n = 4$) (D), and H9C2 ($n = 5$) (E) at 2 hpi ($p < 0.001$ or 0.005). The addition of BLT-1 significantly blocks the LDL-c augmented Spp viral uptake in HDMVEC (B), MØ (C), LDLR^{-/-} MØ (D), and H9C2 (E) at 2 hpi ($p < 0.02$ or 0.001).

(Supplementary Figures 3C and D, Supplementary Table 5). The representative transcriptional signatures of downregulation include gene families from ATP synthases (Complex V), reduced nicotinamide adenine dinucleotide (NADH):ubiquinone oxidoreductase family (NDUF) (Complex I) and cytochrome c oxidases (COX) (Complex IV); the representative transcriptional signatures of upregulation include master transcriptional factor of stress signaling, nuclear factor-erythroid 2-related factor 1 (NFE2L1) and signal transducer and activator of transcription 5A (STAT5A), and glucose metabolic gene clusters.

3.4. Obesity exacerbates Spp-induced long-term aberrances of cardiac transcriptional signatures

We next focused on the Spp-induced long-term changes in cardiac transcriptomes in obese mice. There were no cardiac DE genes found in NCF mice 3 wpi as compared with the NCF control mice at the level of FDR < 0.05 (Supplementary Figure 4C), suggesting that long-term effects on cardiac transcriptome in normal-chow-fed mice were minimal post Spp administration. There were total 209 DE genes (FDR < 0.05) including 69 upregulated and 140 downregulated transcripts in the HFD mice 3 wpi as compared with the HFD control mice

without Spp administration (Figure 3A,B, Supplementary Table 6). The Gene Ontology (GO) analysis showed the enriched downregulated functional annotations were electron transfer activity and proton transmembrane transporter activity; the enriched upregulated functional annotations were GTPase activity and GTP binding. In particular, three clusters of gene families involving mitochondria respiratory chains (MRC) were significantly downregulated including ATP synthases, NDUFs, and COXs. Transcripts from a total of 33 ATP synthase gene members (including 17 pseudogene members) were detected in HFD mouse hearts; Eleven of them (including 7 pseudogene members) showed significant decrease at 3 wpi (FDR < 0.05 , Figure 3C). For NDUF gene family, 9 downregulated DE genes out of 35 detected genes were identified; no upregulated DE genes were found (FDR < 0.05 , Figure 3C). For COX gene family, 3 downregulated DE genes out of 23 detected genes were identified (FDR < 0.05).

We next compared the cardiac transcripts per million (TPM) of these DE gene members from 24 hpi to 3 wpi in both control and obese mice (Figure 4). In the ATP synthase family, ATP5MK (USMG5), ATP5G3 and ATP5C1P1 in HFD mice at 24 hpi to 3 wpi showed significant decreases as compared with the NCF or HFD control mice (FDR < 0.05 , Figure 4A). ATP5L, ATP5C1, ATP5G1P6, ATP5G1P7, ATP5LP5, and




Figure 2: Cardiac Spp viral accumulation in obese mice. (A) Outline of the animal treatment protocol. The C57BL/6J mice (2 months old) were fed normal chow or HFD. The viral administration was given at 5 months later (7 months old). The animals were remained on the same types of diets until being sacrificed at 2 hpi, 24 hpi, 3 wpi, 6 wpi, and 24 wpi. (B) Quantification of serum levels of total cholesterol, LDL/VLDL, and HDL in HFD mice ($n = 7$) and the NCF group ($n = 8$). # indicates $p < 0.01$ for intergroup comparison. (C) The relative protein levels of SR-B1 in hearts ($n = 10$) and adipose tissues ($n = 6$) in HFD mice and the NCF group by Western blot. Blots from two animals per group were shown. # indicates $p < 0.01$ in HFD vs NCF group for SR-B1 with the 75 kd MW band (**). (D) Systemic dissemination of Spp virus in HFD mice. Viral load was determined by ratios of viral mCherry levels to housekeeping gene RPS18 levels in each tissue using a real time RT-PCR (Log 10 scale in Y-axis) ($n = 4-7$ animals per group). & indicates statistical significance in HFD group as compared with normal mice group 2 hpi or 24 hpi. Dashed line: the average Spp level in the lungs at 24 hpi. *, indicates statistical significance at 24 hpi as compared with 2 hpi in adipose tissues from normal chow-fed mice. The datasets of various tissues (except adipose tissues) at 2 and 24 hpi from normal-chow-fed mice were adapted from our previous report [22] for a direct comparison to the datasets from HFD mice. (E) Cellular colocalizations of Spike protein of Spp virus in the HFD hearts at 2 and 24 hpi. An anti-Spike S1 subunit antibody (red) is used to recognize the Spike protein in Spp. An anti-CD31 or anti-MRC1 antibody (green) is used to stain blood vessels or MRC1 in heart, respectively. Yellow arrowhead indicates cells positive for both markers. Blue: DAPI staining for nuclei. Scale bar: 20 μm .

ATP5G1P8 in HFD mice at 3 wpi showed significant decreases as compared with the NCF or HFD control mice ($FDR < 0.05$, Figure 4A). ATP5A1P3 and ATP5HP1 in HFD mice at 3 wpi showed significant decreases as compared with HFD control mice ($FDR < 0.05$, Figure 4A). In the NDUF and COX families, NDUFB11 and COX7A2 in HFD mice at 24 hpi or 3 wpi showed significant decreases as compared with the

NCF or HFD control mice ($FDR < 0.05$, Figure 5B&C). NDUFS3, NDUFS8, NDUFB4P2, NDUFA12, NDUFS4, COX5A, and COX5BP1 in HFD mice at 3 wpi showed significant decreases as compared with NCF or HFD control mice ($FDR < 0.05$, Figure 4B&C). NDUFAB1 and NDUFA3P1 in HFD mice at 3 wpi showed significant decreases as compared with the HFD control mice ($FDR < 0.05$, Figure 4B&C).




Figure 3: Transient administration of Spp virus induces long-term changes in cardiac transcriptome in obese mice. (A) Volcano plot showing the cardiac DEs in HFD mice 3 wpi as compared with control HFD mice. FDR < 0.05 (horizontal dashed line) is used for cut-off threshold. Right vertical dashed line: fold changes (FC) > 0.5 (increase); left vertical dashed line: FC < - 0.5 (decrease). Blue dots represent downregulated DEs (n = 140) and red dots represent upregulated DEs (n = 69). (B) Ranked heatmap showing the individual downregulated (left two panels) and upregulated DE genes (right panel), which is ranked by FDR. (C) Scatter plot showing significant downregulations of gene families in ATP synthases and NDUFs (FDR < 0.05). Dashed lines in both panels represent FC = ± 0.5 levels. Blue dots represent downregulated DE genes in ATP synthase (n = 10 out of 32) or NDUF (n = 9 out of 35) family. N = 3 animals per group for RNA-seq.

There were several functional gene clusters among those 69 upregulated DE transcripts in the HFD mice at 3 wpi as compared with the HFD control mice. The first gene cluster involves stress pathway and kinase activity. NFE2L1, STAT5A and phosphatidylinositol 5-phosphate 4-kinase type-2 beta (PIP4K2B) in HFD mice at 24 hpi or 3 wpi showed significant increases as compared with the NCF or HFD control mice (FDR < 0.05, Figure 5A). Mitofusin 2 (*MFN2*), guanine nucleotide-binding protein subunit alpha-12 (*GNA12*), phosphatidylinositol 4-kinase beta (*PI4KB*), and complement component 3 (*C3*) showed in HFD mice at 3 wpi showed significant increases as compared with the NCF or HFD control mice (FDR < 0.05, Figure 5A). Glioblastoma amplified sequence (GBAS) and G protein-coupled receptor kinase-interacting protein 1 (*GIT1*) in HFD mice at 3 wpi showed significant increases as compared with the HFD mice (FDR < 0.05, Figure 5A). In the gene clusters involving the mitochondria Krebs cycle and cardiovascular functions, glycogen phosphorylase B (*PYGB*) and proprotein convertase subtilisin/kexin type 6 (*PCSK6*) in HFD mice at 24 hpi or 3 wpi showed significant increases as compared with the NCF or HFD control mice (FDR < 0.05, Figure 5B&C). Oxoglutarate dehydrogenase (*OGDH*), solute carrier family 6 member 6 (*SLC6A6*), and scavenger receptor class A member 5 (*SCARA5*) in HFD mice at 3 wpi showed significant increases as compared with the NCF or HFD control groups (FDR < 0.05, Figure 5B&C). Oxoglutarate dehydrogenase L (*OGDHL*), glycogen synthase 1 (*GYS1*), sodium voltage-gated channel alpha subunit 5 (*SCN5A*) and period circadian regulator 1 (*PER1*) in HFD mice at 3 wpi showed significant increases as compared with the HFD control mice (FDR < 0.05, Figure 5B&C). We next examined the long-term changes of some of those DE genes with high abundances (e.g., ATP5L, ATP5G3, NDUFAB1, NDUFA2, NFE2L1, OGDH, PYGB, SCN5A and PER1) in HFD mice using quantitative real time RT-PCR (primers are listed in Supplementary Table 2). The persistent downregulation (ATP5L, ATP5G3, NDUFAB1, and NDUFA2) and upregulation (NFE2L1, OGDH, PYGB, SCN5A and PER1)

of those cardiac DE genes were observed in the HFD mice at 6 or 24 wpi as compared with the age-matched HFD controls (Figure 6A&B, Supplementary Figure 5). We next examined the cardiac protein levels of some representative DE genes. Consistently with their transcriptional profiles, ATP5C1, NDUFS3, and NDUFA2 showed downregulation while the STAT5A, OGDH, and PYGB exhibited upregulation of their cardiac protein levels in HFD mice at 6 wpi as compared with the NCF or HFD control groups (Figure 6C). Next, we re-examined the existing STAT5A-Cistromes database deposited in the Signaling Pathways Project (<http://www.signalingpathways.org/index.jsf>) [31–34]. Through these available experimental ChIP-seq data, STAT5A has been found to the common transcriptional factor that binds in the promoters of most of these DE genes (Supplementary Table 7), suggesting that STAT5A may act as a master transcriptional factor involving regulation of these DE genes.

Finally, we examined the cardiac fibrosis and in vivo cardiac functions. Cross sections of hearts in each group at 6 wpi were examined using Masson's trichrome staining assay. Except basal level of perivascular fibrosis, there was no obvious fibrosis observed in both NCF and NCF_SPP control groups at 6 wpi (Figure 7A–D, Supplementary Figure 6). Interstitial and perivascular fibrosis were moderately and significantly increased in the HFD group at 6 wpi as compared with the basal levels in NCF and NCF_SPP groups (Figure 7D, Supplementary Figure 6). In the HFD_SPP group at 6 wpi, the development of focal fibrosis was evident, exhibiting significantly higher percentages of cardiac fibrotic areas as compared with the other three groups (Figure 7A–D, Supplementary Figure 6). In order to explore the potential inflammatory mediators for the cardiac fibrosis, we examined the DE profiles and found consistent upregulations of some inflammatory mediators such as Angiopoietin Like 2 (*ANGPTL2*), MAPK Activated Protein Kinase 2 (*MAPKAPK2*), and STAT5A in viral-administered HFD mice versus age-matched HFD controls at both 24 hpi and 3 wpi (Supplementary Table 5 and 6). *ANGPTL2* is a




Figure 4: Cardiac DE gene profiles in mitochondria respiratory chain complex in response to viral administration in obese mice. Normalized TPMs for individual DE genes in ATP synthase (A), NDUFA (B), and COX (C) families were plotted crossing six sample groups, e.g., NCF mice control or 24 hpi or 3 wpi, HFD mice control or 24 hpi or 3 wpi. The TPMs were extracted from RNA-seq datasets which was analyzed using an EdgeR/Rstudio package. As compared with HFD mouse controls, these genes typically showed significant decreases in HFD mice 3 wpi but not in other groups. &, FDR <0.05 as compared with HFD mouse control group; #, FDR <0.05 as compared with NCF control mouse group. N = 3 for animals for each group.

proinflammatory protein associated with various chronic inflammatory diseases and MAPKs are among downstream signaling targets [35]. Persistent STAT5 activation is known to promote chronic inflammation [36]. We then performed an IHC to investigate the expression patterns of phosphorylated-STAT5A (p-STAT5A) and p-ERK in the cardiac sections. There were many p-STAT5A and p-ERK positive cells in the focal fibrotic areas at 3 wpi in HFD hearts (Supplementary Figure 7). There was no evident p-STAT5A positive cells in the heart sections from the groups of NCF, NCF + Spp, and HFD (Supplementary Figure 7). There was a basal level of p-ERK signaling in scattered cells in the heart sections from the groups of NCF, NCF + Spp, and HFD, but less intensity than in the cardiac fibrotic areas from the HFD + Spp group (Supplementary Figure 7).

Echocardiogram showed that there was a significant decrease in cardiac ejection fraction (EF) (%) and fractional shortening (FS) (%) in HFD mice at 24 wpi as compared with the age-matched HFD controls (Figure 7E). In addition, the left ventricular end-systolic diameter (LVID s) and volume (LV Vol s) in HFD mice at 24 wpi were significantly increased as compared with the age-matched HFD controls (Figure 7E). There were no significant changes in other parameters between these two groups, including left ventricular end-diastolic diameter (LVID d), left ventricular end-diastolic volume (LV Vol d), left ventricular end-diastolic posterior wall thickness (LVPW d), left

ventricular end-systolic posterior wall thickness (LVPW s), left ventricular end-diastolic anterior wall thickness (LVAW d), left ventricular end-systolic anterior wall thickness (LVAW s), and stroke volume (SV), LV mass, cardiac output, body weight, and heart weight-to-tibia length (Supplementary Figure 8). This data together demonstrates a reduction of myocardial contractility, suggesting a development of myocardial damages.

4. DISCUSSION

This study demonstrates that the Spike protein can induce a long-term transcriptional suppression of gene families related to mitochondria metabolic pathways as well as facilitate cardiac fibrotic development and myocardial contractility reduction in obese mice. It also shows that SR-B1 is a major contributor to the cholesterol-enhanced viral entry into host cells. This data reveals the cardiac pathological features exacerbated by the Spike protein with obesity, providing novel insights into CVD sequelae of PASC.

SR-B1 is a major receptor for trafficking of HDL-c, ox-LDL-c, and LDL-c and LDLr is the receptor for LDL-c uptake. Both are co-receptors for many pathogens entry of host cells with an aid from cholesterol [37–41], making them the leading candidates of co-factors in host cells such as EC, MØ and cardiomyocytes to mediate viral entry in obesity.




Figure 5: Upregulated cardiac DE gene profiles in response to viral administration in obese mice. Normalized TPMs for individual DEs in categories of stress pathway/kinase activity (A), glucose metabolism (B), and cardiovascular functions (C) were plotted crossing six sample groups, e.g., NCF mice control or 24 hpi or 3 wpi, HFD mice control or 24 hpi or 3 wpi. The TPMs were extracted from RNA-seq datasets which was analyzed using an EdgeR/Rstudio package. As compared with HFD mouse controls, these genes typically showed significant increases in HFD mice 3 wpi but not in other groups. &, FDR <0.05 as compared with HFD mouse control group; #, FDR <0.05 as compared with NCF control mouse group. N = 3 for animals for each group.

SARS-2 S1 subunit can bind to HDL-c and facilitate entry into cells via SR-B1 [30]. In this study, we have shown that SR-B1 is the major receptor for LDL-c or HDL-c-mediated enhancement of viral entry. As the fact that obese patients generally have elevated LDL-c levels and decreased HDL-c levels in the blood [42], we posit that LDL-c is preferably exploited by SARS-CoV-2 for viral entry in obesity. We have shown that cardiac and adipocytic but not pulmonary SR-B1 are increased in HFD-fed mice. This may explain the selective viral uptake in heart and blood vessels but not in lungs in obese mice, providing insightful information regarding the mechanism that patients with preconditions such as CVD, hypertension, and obesity have high risks to be infected and develop severe symptoms.

The potential roles of cardiac mitochondria perpetuations in CVD sequelae of PASC are yet to be determined. HFD has no effect on membrane potentials, redox profiles, and ATP synthases, but induces increased rates of electron leak, on cardiac mitochondria [43]. Therefore, the long-term transcriptomic changes in MRC genes may be a result from a viral administration and HFD. In addition, STAT5A has been revealed to be dysregulated in response to a viral administration and HFD in this study. Many of the DE transcripts of MRC genes have a binding motif of STAT5A, suggesting that STAT5A may serve as the

master transcriptional factor in controlling their expressions. Our data has been supported by and consistent with various reports in actual infection system or patients. For example, evidence has shown mitochondrial dysfunction, metabolic alterations with an increase in glycolysis, and high levels of mitokine in PBMCs from patients with COVID-19 [44]. Lower levels of mitochondrial membrane potential were found in the elderly who had symptoms suggestive of COVID-19 or with a confirmed diagnosis of COVID-19 [45]. SARS-CoV-2 can cause transcriptional downregulation of mitochondria-related processes, respiratory electron transport chain, and ATP synthesis coupled electron transport in the lung epithelial cell line A549 [46]. Another study has shown that SARS-CoV-2 can downregulate electron transport chain complex I and ATP synthase genes in human airway epithelial cells [47]. Depolarized mitochondria and abnormal mitochondrial ultrastructure have been found in monocytes in patients with COVID-19 [48]. Dysfunctional mitochondria-dependent lipid catabolism is found in the plasma of patients with PASC [49]. This accumulative evidence and our data together have shown that SARS-CoV-2 infection can induce mitochondriopathy in COVID-19. The mitochondria have been identified as an important drug target for the next wave of cardiac drugs since their dysfunction is closely associated with cardiac




Figure 6: Long-term changes in cardiac DE transcripts in obese mice in response to viral administration. Real time RT-PCR assay was performed to evaluate the relative mRNA levels of representative downregulated (A) and upregulated (B) DE transcripts in the following groups, NCF or HFD mice post Spp administration for 6 or 24 wpi, age-matched NCF or HFD control mouse groups (8.5 or 13 months old). (C) Relative cardiac protein levels of some representative DE genes such as ATP5C1, NDUFS3, NDUFA2, OGDH, PYGB, and STAT5A at 6 wpi using Western blot assay. #, $p < 0.05$ as compared with the age-matched control groups with matching ages using two sample t test. $N = 3$ for animals for each group.

function declines and heart failure [50]. Therefore, targeting the mitochondrial metabolic pathways may provide a potential new avenue of treatment for cardiovascular-associated symptoms in PASC. The molecular mechanisms underlying PASC remain elusive. Our data has demonstrated direct viral attack to heart is one of the mechanisms underlying PASC. Another theory is that active viral reservoirs or/and persistent circulating Spike may be associated with PASC symptoms. Our data has shown adipose tissue is one of the preferable organs for viruses to accumulate. This supports the hypothesis that adipocytes

serve as a reservoir of SARS-CoV-2 [51]. Thus, it is reasonable to posit is that infected adipocytes could release Spike-protein-harbored extracellular vesicles, which could result in an uptake of these vesicles into cardiomyocytes thus exaggerating cardiomyopathy induced by obesity. Persistent circulating Spike protein and/or viral RNA have been found in patients with PASC [52–54]; In addition, the Spike protein is efficiently incorporated into cell membranes [9] and has been found in viral RNA-absent extracellular vesicles in patient blood [53]. This may evade from a recognition by neutralized antibodies, resulting




Figure 7: Development of cardiac fibrosis and cardiac functional changes in obese mice in response to viral administration. (A) Masson's trichrome staining on heart cross sections at 6 wpi. The development of focal fibrosis is evident in the HFD_SPP group (black boxed area). (B) A high magnification of the boxed area in the HFD_SPP group in (A). (C) A high magnification of the boxed area in (B). The blue arrowhead indicates the focal fibrotic areas. (D) Quantitative analysis of the percentage of fibrotic areas in each group. Mann–Whitney test was used to compare the differences among two groups. Whiskers are presented as mean \pm S.D. with the diamond boxed showing interquartile ranges of the data. N = 5 sections for NCF group, 8 for NCF_SPP group, 24 for HFD and 24 for HFD_Spp group from 3 animals per group. (E) Comparison of echo parameters such as EF (%), FS (%), LV Vol s (μ L), and LVID s (mm) between the HFD mice 24 wpi and the age-matched HFD controls (13 months old). #, $p < 0.05$. N = 5 animals per group. (F) A proposed mechanistic model for cardiomyopathy in PASC under obese conditions which are likely resulted from multifactorial contributions: spike protein impairs lipid metabolisms and increases lipotoxicity-associated ferroptosis; lipids promote viral administration and facilitate cardiac viral accumulation; and viral administration exaggerates obesity-induced persistent chronic inflammation, enhances glucose metabolism, compensates cardiovascular functions, systemically suppresses expression of MRC gene families, decreases cardiac myocardial contractility, and increases cardiac fibrosis.

in a persistent and systemic distribution and prolonged lifetime of the Spike protein. Multiple studies have shown that the Spike protein can induce non-infective cardiovascular stress, including disruption of human cardiac pericytes function, vascular endothelial cells, and the blood–brain barrier [6,8,55]. We further evidence of this showing that the Spike protein can cause a long-term transcriptional suppression in MRC gene families. This accumulative data together provides an insight into the potential role of the Spike protein in the pathogenesis of PASC.

There are several limitations for this study. (1) The Spp lentivirus cannot completely replicate the pathological process of SARS-CoV-2 in human. However, it can be handled in a BLS2 facility and has been shown to be a very useful system to investigate the Spike protein-mediated cell type susceptibility, host tropism for infection and pathogenicity [22,56]. Thus, it is a valuable tool to study the potential role of Spike protein in PASC. (2) This study does not simulate the nature of the entry pathway of SARS-CoV-2 through upper airway, which is a limitation. The PASCs are associated with the persistent and chronic presence of extrapulmonary residual viral components through circulatory system [52–54]. For example, an dissemination of SARS-CoV-2 RNA has been found in multiple organs even over 7 months in some patients; particularly, residue viral RNA can be detectable in the cardiovascular system including myocardium, pericardium, endothelium, aorta, and vena cava in 80% patients [57]. Another study has corroborated that the Spike and nucleocapsid proteins of SARS-CoV-2 are present in GI, hepatic tissues, and lymph nodes in recovered patients with COVID-19 over 6 months [58]. This evidence suggests the role of extrapulmonary viral burdens in PASC, which is distinct from the primary nasal infection pathway. Our pseudoviral model only mimics this secondary infection process and the Spike protein associated prolonged pathologies. (3) Our results can only be applicable to the Wuhan variant of Spike protein which is also the first step to enlighten the molecular mechanisms underlying CVD PASC. Clinical evidence has shown CVD PASC symptoms in patients infected by the Wuhan original strain. For example, Palpitation and tachycardia were reported in patients infected with the Wuhan variant in the cohorts from Spain and Italy [59,60]. In U.S., long-term CVD sequelae was early reported from a cohort in Michigan (6 March to 1 July 2020) [61] and a cohort of veterans (1 March 2020 to 15 January 2021) [20]. Those CVD PASC were posited to be mainly caused by the infection of the Wuhan variant since the alpha variant first appeared late November 2020 [62] and was consisted of 1.0% of total cases by the 2nd week of January 2021 in the U.S [63]. The evolutionary mutating of the Spike protein has led to several variants of concern (VOC) including Alpha, Beta, Gamma, Delta, and the current Omicron, resulting in less pathogenicity but higher transmissibility [64,65]. Our data may not reflect the mechanism of CVD PASC caused by the current dominant Omicron strain, which is a limitation for this study. However, the significance of mechanistic studies of CVD PASC caused by the original variant of Spike protein shouldn't be undervalued as this variant presents a higher pathogenicity than other VOCs. Our data will also strengthen future studies that include the Omicron and other variants to elucidate this mechanism in a systemic spectrum. (4) The functional changes in cardiac mitochondria, metabolism, and rhythms have not been elicited in this model, which will be the focus in the next investigations. (5) The small but significant decreases in EF in our model suggested an impairment of cardiac contractile, an onset towards development of cardiac dysfunction. Other measurements for contractile parameters

using ex vivo models and in the isolated cardiomyocytes will be needed in future to further characterize the pathological changes at this stage.

In summary, we have provided an insight to the mechanisms underlying cardiac sequelae of PASC (Figure 7F). First, cholesterol such as LDL-c can enhance viral entry into host cells *in vitro* and obesity can cause selective viral accumulation in heart, aorta, and adipose tissues, demonstrating that lipid and obesity can particularly facilitate the viral burden in cardiovascular system. Second, the Spike protein alone can impair lipid metabolic and autophagic pathways thus augment the lipid overload-induced ferroptosis [9]. Third, consistent chronic inflammations are exacerbated in HFD hearts with addition of viral infection. Fourth, the downregulation of transcriptional profiles of MRC gene families indicates a perturbation of mitochondria energy production as a long-term cardiac sequela upon Spp viral burden under obese conditions. Fifth, upregulation of glucose metabolic-related genes implies imbalance of cardiac fatty acid oxidation (FAO)-produced ATPs. Sixth, increases in cardiovascular function-related transcripts suggest cardiac functional compensation and restoration in response to chronic inflammation-induced metabolic aberrances in hearts. Seventh, the increased cardiac fibrosis is evident. Eighth, the decreased cardiac EF and FS and increased LVID s and LV Vol s demonstrate reductions of myocardial contractility. This data suggests a development of cardiac damages towards an onset of evident functional impairments. Collectively, our data have shown the Spike protein induces transcriptional suppression of cardiac mitochondrial metabolic genes, cardiac fibrosis, and reduction of myocardial contractility in obese mice, providing a mechanistic insight to cardiomyopathy sequelae of PASC.

DISCLAIMER

Any views expressed here represent personal opinion and do not necessarily reflect those of the U.S. Department of Health and Human Services or the United States federal government.

PRIOR PUBLICATION

None of the material in this manuscript has been published or is under consideration for publication elsewhere, including the Internet.

FUNDING STATEMENT

This work was supported by grants from the National Institutes of Health (R01 AR073172 and NIH COBRE (P20GM109091, pilot study) to W.T., NSF EPSCoR (OIA1736150) to H.K., R01 HL160541 to T.C.).

CREDIT AUTHORSHIP CONTRIBUTION STATEMENT

Xiaoling Cao, Conceptualization, Animal study Conduct, Data Analysis, Methodology, Project administration. **Vi Nguyen**, Conceptualization, In vitro study Conduct, echocardiography, Data analysis, Methodology. **Chao Gao**, Study Conduct including serum lipid determination and mitochondria staining. **Joseph Tsai**, NGS data analysis; **Yan Tian**, Study Conduct, Data Analysis. **Yuping Zhang**, Study Conduct, Data Analysis. **Wayne Carver**, Writing — review and editing. **Hippokratis Kiaris**, Conceptualization, Writing — review and editing, funding acquisition. **Taixing Cui**, Conceptualization, Writing — review and editing, funding acquisition. **Wenbin Tan**, Conceptualization, Writing — original drafting, review and editing funding acquisition.

DATABASE DEPOSITION

Gene expression and transcriptome obtained from NGS are available in the [Supplementary Tables 3-6](#). The raw data (reads) of NGS are deposited into SRA (Sequence Read Archive) with an accession as PRJNA985066 (<https://www.ncbi.nlm.nih.gov/bioproject/PRJNA985066>)

DECLARATION OF COMPETING INTEREST

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

DATA AVAILABILITY

Data will be made available on request.

ACKNOWLEDGEMENTS

We are very thankful to the support and assistance from Instrumentation Resource Facility at the University of South Carolina School of Medicine. We are very grateful to the support from Dr. Igor Roninson and the COBRE Center for Targeted Therapeutics at the University of South Carolina.

APPENDIX A. SUPPLEMENTARY DATA

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.molmet.2023.101756>.

REFERENCES

- [1] The species severe acute respiratory syndrome-related coronavirus: classifying 2019-ncov and naming it sars-cov-2. *Nat Microbiol* 2020. <https://doi.org/10.1038/s41564-020-0695-z>.
- [2] Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the sars-cov-2 spike glycoprotein. *Cell* 2020;181:281–292 e286. <https://doi.org/10.1016/j.cell.2020.02.058>.
- [3] Cantuti-Castelvetri L, Ojha R, Pedro LD, Djannatian M, Franz J, Kuivanen S, et al. Neuropilin-1 facilitates sars-cov-2 cell entry and infectivity. *Science* 2020;370:856–60. <https://doi.org/10.1126/science.abd2985>.
- [4] Daly JL, Simonetti B, Klein K, Chen KE, Williamson MK, Anton-Plagaro C, et al. Neuropilin-1 is a host factor for sars-cov-2 infection. *Science* 2020;370:861–5. <https://doi.org/10.1126/science.abd3072>.
- [5] Singh RD, Barry MA, Croatt AJ, Ackerman AW, Grande JP, Diaz RM, et al. The spike protein of sars-cov-2 induces heme oxygenase-1: pathophysiologic implications. *Biochim Biophys Acta, Mol Basis Dis* 2022;1868:166322. <https://doi.org/10.1016/j.bbadis.2021.166322>.
- [6] Lei Y, Zhang J, Schiavon CR, He M, Chen L, Shen H, et al. Sars-cov-2 spike protein impairs endothelial function via downregulation of ace 2. *Circ Res* 2021;128:1323–6. <https://doi.org/10.1161/CIRCRESAHA.121.318902>.
- [7] Bortolotti D, Gentili V, Rizzo S, Rotola A, Rizzo R. Sars-cov-2 spike 1 protein controls natural killer cell activation via the hla-e/nkg2a pathway. *Cells* 2020;9. <https://doi.org/10.3390/cells9091975>.
- [8] Avolio E, Carrabba M, Milligan R, Kavanagh Williamson M, Beltrami AP, Gupta K, et al. The sars-cov-2 spike protein disrupts human cardiac pericytes function through cd147 receptor-mediated signalling: a potential non-infective mechanism of covid-19 microvascular disease. *Clin Sci (Lond)* 2021;135:2667–89. <https://doi.org/10.1042/CS20210735>.
- [9] Nguyen V, Zhang Y, Gao C, Cao X, Tian Y, Carver W, et al. The spike protein of sars-cov-2 impairs lipid metabolism and increases susceptibility to lipotoxicity: implication for a role of nrf2. *Cells* 2022;11. <https://doi.org/10.3390/cells11121916>.
- [10] Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with covid-19 in the New York city area. *JAMA* 2020. <https://doi.org/10.1001/jama.2020.6775>.
- [11] Fan J, Wang H, Ye G, Cao X, Xu X, Tan W, et al. Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019. *Metabolism* 2020;154:243. <https://doi.org/10.1016/j.metabol.2020.154243>.
- [12] Wei X, Zeng W, Su J, Wan H, Yu X, Cao X, et al. Hypolipidemia is associated with the severity of covid-19. *J Clin Lipidol* 2020. <https://doi.org/10.1016/j.jacl.2020.04.008>.
- [13] Cao X, Yin R, Albrecht H, Fan D, Tan W. Cholesterol: a new game player accelerating endothelial injuries caused by sars-cov-2? *Am J Physiol Endocrinol Metab* 2020. <https://doi.org/10.1152/ajpendo.00255.2020>.
- [14] Li G, Du L, Cao X, Wei X, Jiang Y, Lin Y, et al. Follow-up study on serum cholesterol profiles and potential sequelae in recovered covid-19 patients. *BMC Infect Dis* 2021;21:299. <https://doi.org/10.1186/s12879-021-05984-1>.
- [15] Lu Y1, Liu Tam JP DX. Lipid rafts are involved in sars-cov entry into vero e6 cells. *Biochem Biophys Res Commun* 2008;369:6. <https://doi.org/10.1016/j.bbrc.2008.02.023>.
- [16] Toelzer C, Gupta K, Yadav SKN, Borucu U, Davidson AD, Kavanagh Williamson M, et al. Free fatty acid binding pocket in the locked structure of sars-cov-2 spike protein. *Science* 2020;370:725–30. <https://doi.org/10.1126/science.abd3255>.
- [17] Shoemark D, Colenso C, Toelzer C, Gupta K, Sessions R, Davidson A, et al. Molecular simulations suggest vitamins, retinoids and steroids as ligands binding the free fatty acid pocket of sars-cov-2 spike protein. *ChemRxiv* 2020. <https://doi.org/10.26434/chemrxiv.13143761.v1>.
- [18] Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute covid-19 syndrome. *Nat Med* 2021;27:601–15. <https://doi.org/10.1038/s41591-021-01283-z>.
- [19] Raman B, Bluemke DA, Luscher TF, Neubauer S. Long covid: post-acute sequelae of covid-19 with a cardiovascular focus. *Eur Heart J* 2022;43:1157–72. <https://doi.org/10.1093/eurheartj/ehac031>.
- [20] Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of covid-19. *Nat Med* 2022;28:583–90. <https://doi.org/10.1038/s41591-022-01689-3>.
- [21] Scherer PE, Kirwan JP, Rosen CJ. Post-acute sequelae of covid-19: a metabolic perspective. *Elife* 2022;11. <https://doi.org/10.7554/eLife.78200>.
- [22] Cao X, Tian Y, Nguyen V, Zhang Y, Gao C, Yin R, et al. Spike protein of sars-cov-2 activates macrophages and contributes to induction of acute lung inflammation in male mice. *Faseb J* 2021;35:e21801. <https://doi.org/10.1096/fj.202002742RR>.
- [23] Wang CY, Liao JK. A mouse model of diet-induced obesity and insulin resistance. *Methods Mol Biol* 2012;821:421–33. https://doi.org/10.1007/978-1-61779-430-8_27.
- [24] Tschope C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB, et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. *Nat Rev Cardiol* 2021;18:169–93. <https://doi.org/10.1038/s41569-020-00435-x>.
- [25] Fairweather D, Beetler DJ, Musigk N, Heidecker B, Lyle MA, Cooper Jr LT, et al. Sex and gender differences in myocarditis and dilated cardiomyopathy: an update. *Front Cardiovasc Med* 2023;10:1129348. <https://doi.org/10.3389/fcvm.2023.1129348>.
- [26] Kharroubi SA, Diab-El-Harake M. Sex-differences in covid-19 diagnosis, risk factors and disease comorbidities: a large us-based cohort study. *Front Public Health* 2022;10:1029190. <https://doi.org/10.3389/fpubh.2022.1029190>.

- [27] Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. Star: ultrafast universal rna-seq aligner. *Bioinformatics* 2013;29:15–21. <https://doi.org/10.1093/bioinformatics/bts635>.
- [28] Liao Y, Smyth GK, Shi W. Featurecounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics* 2014;30:923–30. <https://doi.org/10.1093/bioinformatics/btt656>.
- [29] Zang H, Wu W, Qi L, Tan W, Nagarkatti P, Nagarkatti M, et al. Autophagy inhibition enables nrf2 to exaggerate the progression of diabetic cardiomyopathy in mice. *Diabetes* 2020;69:2720–34. <https://doi.org/10.2337/db19-1176>.
- [30] Wei C, Wan L, Yan Q, Wang X, Zhang J, Yang X, et al. Hdl-scavenger receptor b type 1 facilitates sars-cov-2 entry. *Nat Metab* 2020;2:1391–400. <https://doi.org/10.1038/s42255-020-00324-0>.
- [31] Gertz J, Savic D, Varley KE, Partridge EC, Safi A, Jain P, et al. Distinct properties of cell-type-specific and shared transcription factor binding sites. *Mol Cell* 2013;52:25–36. <https://doi.org/10.1016/j.molcel.2013.08.037>.
- [32] Zhu BM, Kang K, Yu JH, Chen W, Smith HE, Lee D, et al. Genome-wide analyses reveal the extent of opportunistic stat5 binding that does not yield transcriptional activation of neighboring genes. *Nucleic Acids Res* 2012;40:4461–72. <https://doi.org/10.1093/nar/gks056>.
- [33] Shin HY, Willli M, HyunYoo K, Zeng X, Wang C, Metser G, et al. Hierarchy within the mammary stat5-driven wap super-enhancer. *Nat Genet* 2016;48:904–11. <https://doi.org/10.1038/ng.3606>.
- [34] Villarino A, Laurence A, Robinson GW, Bonelli M, Dema B, Afzali B, et al. Signal transducer and activator of transcription 5 (stat5) paralog dose governs t cell effector and regulatory functions. *Elife* 2016;5. <https://doi.org/10.7554/eLife.08384>.
- [35] Thorin-Trescases N, Thorin E. High circulating levels of angpt2: beyond a clinical marker of systemic inflammation. *Oxid Med Cell Longev* 2017;2017:1096385. <https://doi.org/10.1155/2017/1096385>.
- [36] Loh CY, Arya A, Naema AF, Wong WF, Sethi G, Looi CY. Signal transducer and activator of transcription (stats) proteins in cancer and inflammation: functions and therapeutic implication. *Front Oncol* 2019;9:48. <https://doi.org/10.3389/fonc.2019.00048>.
- [37] Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis c virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. *Proc Natl Acad Sci U S A* 1999;96:12766–71. <https://doi.org/10.1073/pnas.96.22.12766>.
- [38] Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, et al. Cell entry of hepatitis c virus requires a set of co-receptors that include the cd81 tetraspanin and the sr-b1 scavenger receptor. *J Biol Chem* 2003;278:41624–30. <https://doi.org/10.1074/jbc.M305289200>.
- [39] Neculai D, Schwake M, Ravichandran M, Zunke F, Collins RF, Peters J, et al. Structure of limp-2 provides functional insights with implications for sr-bi and cd36. *Nature* 2013;504:172–6. <https://doi.org/10.1038/nature12684>.
- [40] Rodrigues CD, Hannus M, Prudencio M, Martin C, Goncalves LA, Portugal S, et al. Host scavenger receptor sr-bi plays a dual role in the establishment of malaria parasite liver infection. *Cell Host Microbe* 2008;4:271–82. <https://doi.org/10.1016/j.chom.2008.07.012>.
- [41] Langlois AC, Manzoni G, Vincensini L, Coppee R, Marinach C, Guerin M, et al. Molecular determinants of sr-b1-dependent plasmodium sporozoite entry into hepatocytes. *Sci Rep* 2020;10:13509. <https://doi.org/10.1038/s41598-020-70468-2>.
- [42] Klop B, Elte JW, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. *Nutrients* 2013;5:1218–40. <https://doi.org/10.3390/nu5041218>.
- [43] Fisher-Wellman KH, Draper JA, Davidson MT, Williams AS, Narowski TM, Slentz DH, et al. Respiratory phenomics across multiple models of protein hyperacetylation in cardiac mitochondria reveals a marginal impact on bioenergetics. *Cell Rep* 2019;26:1557–1572 e1558. <https://doi.org/10.1016/j.celrep.2019.01.057>.
- [44] Ajaz S, McPhail MJ, Singh KK, Mujib S, Trovato FM, Napoli S, et al. Mitochondrial metabolic manipulation by sars-cov-2 in peripheral blood mononuclear cells of patients with covid-19. *Am J Physiol Cell Physiol* 2021;320:C57–65. <https://doi.org/10.1152/ajpcell.00426.2020>.
- [45] Grossini E, Concina D, Rinaldi C, Russotto S, Garhwal D, Zeppegno P, et al. Association between plasma redox state/mitochondria function and a flu-like syndrome/covid-19 in the elderly admitted to a long-term care unit. *Front Physiol* 2021;12:707587. <https://doi.org/10.3389/fphys.2021.707587>.
- [46] Singh K, Chen YC, Hassanzadeh S, Han K, Judy JT, Seifuddin F, et al. Network analysis and transcriptome profiling identify autophagic and mitochondrial dysfunctions in sars-cov-2 infection. *Front Genet* 2021;12:599261. <https://doi.org/10.3389/fgene.2021.599261>.
- [47] Archer SL, Dasgupta A, Chen KH, Wu D, Baid K, Mamatis JE, et al. Sars-cov-2 mitochondriopathy in covid-19 pneumonia exacerbates hypoxemia. *Redox Biol* 2022;58:102508. <https://doi.org/10.1016/j.redox.2022.102508>.
- [48] Gibellini L, De Biasi S, Paolini A, Borella R, Boraldi F, Mattioli M, et al. Altered bioenergetics and mitochondrial dysfunction of monocytes in patients with covid-19 pneumonia. *EMBO Mol Med* 2020;12:e13001. <https://doi.org/10.15252/emmm.202013001>.
- [49] Guntur VP, Nemkov T, de Boer E, Mohning MP, Baraghoshi D, Cendali FI, et al. Signatures of mitochondrial dysfunction and impaired fatty acid metabolism in plasma of patients with post-acute sequelae of covid-19 (pasc). *Metabolites* 2022;12. <https://doi.org/10.3390/metabo12111026>.
- [50] Brown DA, Perry JB, Allen ME, Sabbah HN, Stauffer BL, Shaikh SR, et al. Expert consensus document: mitochondrial function as a therapeutic target in heart failure. *Nat Rev Cardiol* 2017;14:238–50. <https://doi.org/10.1038/nrcardio.2016.203>.
- [51] Steenblock C, Bechmann N, Beuschlein F, Wolfrum C, Bornstein SR. Do adipocytes serve as a reservoir for sars-cov-2? *J Endocrinol* 2023. <https://doi.org/10.1530/JOE-23-0027>.
- [52] Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, et al. Persistent circulating sars-cov-2 spike is associated with post-acute covid-19 sequelae. *Clin Infect Dis* 2022. <https://doi.org/10.1093/cid/ciac722>.
- [53] Vaughn Craddock, Aatish Mahajan, Balaji Krishnamachary, Spikes Leslie, Prabhakar Chalise, Dhillon NK. Persistent presence of spike protein and viral rna in the circulation of individuals with post-acute sequelae of covid-19. medRxiv 2022. <https://doi.org/10.1101/2022.08.07.22278520>.
- [54] Patterson BK, Francisco EB, Yogendra R, Long E, Pise A, Rodrigues H, et al. Persistence of sars cov-2 s1 protein in cd16+ monocytes in post-acute sequelae of covid-19 (pasc) up to 15 months post-infection. *Front Immunol* 2021;12:746021. <https://doi.org/10.3389/fimmu.2021.746021>.
- [55] DeOre BJ, Tran KA, Andrews AM, Ramirez SH, Galie PA. Sars-cov-2 spike protein disrupts blood-brain barrier integrity via rhoa activation. *J Neuro-immune Pharmacol* 2021;16:722–8. <https://doi.org/10.1007/s11481-021-10029-0>.
- [56] Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. Characterization of spike glycoprotein of sars-cov-2 on virus entry and its immune cross-reactivity with sars-cov. *Nat Commun* 2020;11:1620. <https://doi.org/10.1038/s41467-020-15562-9>.
- [57] Chertow D, Stein S, Ramelli A, Grazioli A, Chung J, Singh M, et al. Sars-cov-2 infection and persistence throughout the human body and brain. *Behavior Modification* 2021. <https://doi.org/10.21203/rs.3.rs-1139035/v1>.
- [58] Cheung CCL, Goh D, Lim X, Tien TZ, Lim JCT, Lee JN, et al. Residual sars-cov-2 viral antigens detected in gi and hepatic tissues from five recovered patients with covid-19. *Gut* 2022;71:226–9. <https://doi.org/10.1136/gutjnl-2021-324280>.
- [59] Fernandez-de-Las-Penas C, Cancela-Cilleruelo I, Rodriguez-Jimenez J, Gomez-Mayordomo V, Pellicer-Valero OJ, Martin-Guerrero JD, et al. Associated-onset symptoms and post-covid-19 symptoms in hospitalized covid-19 survivors infected with wuhan, alpha or delta sars-cov-2 variant. *Pathogens* 2022;11. <https://doi.org/10.3390/pathogens11070725>.

- [60] Spinicci M, Graziani L, Tilli M, Nkurunziza J, Vellere I, Borchini B, et al. Infection with sars-cov-2 variants is associated with different long covid phenotypes. *Viruses* 2022;14. <https://doi.org/10.3390/v14112367>.
- [61] Chopra V, Flanders SA, O'Malley M, Malani AN, Prescott HC. Sixty-day outcomes among patients hospitalized with covid-19. *Ann Intern Med* 2021;174: 576–8. <https://doi.org/10.7326/M20-5661>.
- [62] Washington NL, Gangavarapu K, Zeller M, Bolze A, Cirulli ET, Schiabor Barrett KM, et al. Emergence and rapid transmission of sars-cov-2 b.1.1.7 in the United States. *Cell* 2021;184:2587–2594 e2587. <https://doi.org/10.1016/j.cell.2021.03.052>.
- [63] Helix. The helix® covid-19 surveillance dashboard. 2021:Trends in S Gene Target Failure (SGTF), interactive data map: B.1.1.7 weekly share calculated as the average of the daily B.1.1.7 shares of the week. Daily B.1.1.7 shares are found by multiplying “Daily Percent SGTF of Positive Samples” and B.1.1.7 as % of sequenced SGTF positives.
- [64] Lopez-Cortes GI, Palacios-Perez M, Velediaz HF, Hernandez-Aguilar M, Lopez-Hernandez GR, Zamudio GS, et al. The spike protein of sars-cov-2 is adapting because of selective pressures. *Vaccines (Basel)* 2022. <https://doi.org/10.3390/vaccines10060864>.
- [65] Wang C, Liu B, Zhang S, Huang N, Zhao T, Lu QB, et al. Differences in incidence and fatality of covid-19 by sars-cov-2 omicron variant versus delta variant in relation to vaccine coverage: a world-wide review. *J Med Virol* 2022. <https://doi.org/10.1002/jmv.28118>.